Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in Relapsed/Refractory ALL
NCT02484430Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Apr 2017; status: completed.
02
Drugs
sapanisertib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02484430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484430.